Despite these limitations, our study not only contribute to our understanding of the role of CMTM6 in tumor growth in HCC, but will also lead to the characterization of a specific HCC patients’ group with CMTM6 overexpression who may benefit from TACE. The gene discussed is CMTM6; the disease is hepatocellular carcinoma.